Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares are trading higher after the company announced the expansion of its FDA-cleared first-in-human clinical trial for cancer patients of HT-001 at the University of Miami. This First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose-ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with E…

Read More